NasdaqGS:SGRY

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States. More Details


Snowflake Analysis

Adequate balance sheet with concerning outlook.


Similar Companies

Share Price & News

How has Surgery Partners's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SGRY's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-17.9%

SGRY

-3.6%

US Healthcare

-1.9%

US Market


1 Year Return

165.6%

SGRY

15.9%

US Healthcare

13.1%

US Market

Return vs Industry: SGRY exceeded the US Healthcare industry which returned 15.9% over the past year.

Return vs Market: SGRY exceeded the US Market which returned 13.1% over the past year.


Shareholder returns

SGRYIndustryMarket
7 Day-17.9%-3.6%-1.9%
30 Day6.5%-5.7%-2.9%
90 Day85.2%-1.9%8.2%
1 Year165.6%165.6%17.4%15.9%15.7%13.1%
3 Year89.2%89.2%23.1%17.7%38.4%29.1%
5 Yearn/a51.0%40.3%89.3%68.0%

Price Volatility Vs. Market

How volatile is Surgery Partners's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Surgery Partners undervalued compared to its fair value and its price relative to the market?

4.72x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate SGRY's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate SGRY's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SGRY is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.

PE vs Market: SGRY is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SGRY's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SGRY is overvalued based on its PB Ratio (4.7x) compared to the US Healthcare industry average (2.7x).


Next Steps

Future Growth

How is Surgery Partners forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

67.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SGRY is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SGRY is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SGRY is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SGRY's revenue (10.3% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: SGRY's revenue (10.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SGRY is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Surgery Partners performed over the past 5 years?

-45.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SGRY is currently unprofitable.

Growing Profit Margin: SGRY is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SGRY is unprofitable, and losses have increased over the past 5 years at a rate of 45% per year.

Accelerating Growth: Unable to compare SGRY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SGRY is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).


Return on Equity

High ROE: SGRY has a negative Return on Equity (1.3%), as it is currently unprofitable.


Next Steps

Financial Health

How is Surgery Partners's financial position?


Financial Position Analysis

Short Term Liabilities: SGRY's short term assets ($746.5M) exceed its short term liabilities ($571.2M).

Long Term Liabilities: SGRY's short term assets ($746.5M) do not cover its long term liabilities ($3.0B).


Debt to Equity History and Analysis

Debt Level: SGRY's debt to equity ratio (154.5%) is considered high.

Reducing Debt: SGRY's debt to equity ratio has reduced from 639.1% to 154.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SGRY has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SGRY is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 21.8% per year.


Next Steps

Dividend

What is Surgery Partners's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SGRY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SGRY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SGRY's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SGRY's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SGRY's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.8yrs

Average management tenure


CEO

J. Evans (42 yo)

0.67

Tenure

US$4,789,837

Compensation

Mr. J. Eric Evans has been the Chief Executive Officer and Director at Surgery Partners, Inc. since January 13, 2020 and served as its Executive Vice President and Chief Operating Officer since April 1, 20 ...


CEO Compensation Analysis

Compensation vs Market: J.'s total compensation ($USD4.79M) is above average for companies of similar size in the US market ($USD3.02M).

Compensation vs Earnings: Insufficient data to compare J.'s compensation with company performance.


Leadership Team

NamePositionTenureCompensationOwnership
Wayne DeVeydt
Executive Chairman0.67yrUS$3.63m0.57%
$ 5.5m
J. Evans
CEO & Director0.67yrUS$4.79m0.54%
$ 5.2m
Thomas Cowhey
Executive VP & CFO2.42yrsUS$2.89m0.26%
$ 2.5m
Jennifer Baldock
Executive VP0.58yrUS$1.87m0.34%
$ 3.2m
George Goodwin
President of ASC Group5.83yrsUS$1.69m0.21%
$ 2.1m
Clifford Adlerz
Consultant & Director2.92yrsUS$215.00k0.066%
$ 637.0k
Matt Petty
Senior VP & Chief Information Officer6.67yrsno datano data
Roxanne Womack
Senior VP & Chief Compliance Officer1.83yrsno datano data
Laura Brocklehurst
Senior VP & Chief Human Resources Officer1.17yrsno datano data
Anthony Taparo
Chief Growth Officer1.08yrsno data0.23%
$ 2.2m
Brad Owens
National Group President0.75yrno datano data
Dennis Dean
Executive Officer2.08yrsUS$963.19k0.24%
$ 2.3m

1.8yrs

Average Tenure

50yo

Average Age

Experienced Management: SGRY's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Wayne DeVeydt
Executive Chairman0.67yrUS$3.63m0.57%
$ 5.5m
J. Evans
CEO & Director0.67yrUS$4.79m0.54%
$ 5.2m
Clifford Adlerz
Consultant & Director2.92yrsUS$215.00k0.066%
$ 637.0k
William Turner
Independent Director4.75yrsUS$230.00k0.081%
$ 782.3k
Teresa DeLuca
Independent Director4yrsUS$215.00k0.058%
$ 558.6k
John Deane
Independent Director1.33yrsUS$196.25k0.019%
$ 187.5k
T. O'Reilly
Director3.08yrsno datano data
Andrew Kaplan
Director2.08yrsno datano data

2.5yrs

Average Tenure

52yo

Average Age

Experienced Board: SGRY's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: SGRY insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.2%.


Top Shareholders

Company Information

Surgery Partners, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Surgery Partners, Inc.
  • Ticker: SGRY
  • Exchange: NasdaqGS
  • Founded: 2004
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$965.149m
  • Shares outstanding: 49.78m
  • Website: https://www.surgerypartners.com

Number of Employees


Location

  • Surgery Partners, Inc.
  • 310 Seven Springs Way
  • Suite 500
  • Brentwood
  • Tennessee
  • 37027
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SGRYNasdaqGS (Nasdaq Global Select)YesNew Common StockUSUSDOct 2015
1SPDB (Deutsche Boerse AG)YesNew Common StockDEEUROct 2015

Biography

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States. The company operates through three segments: Surgical Facilit ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/24 06:19
End of Day Share Price2020/09/23 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.